Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> MutationRachna T. Shroff, Susan M. Domchek, Andrew Hendifar et al.|JCO Precision Oncology|2018Cited by 177
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysisChee Khoon Lee, Clare L. Scott, Ursula A. Matulonis et al.|Cancer|2021Cited by 37
RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic <i>BRCA</i> mutation.Susan M. Domchek, Rachna T. Shroff, Kevin Lin et al.|Journal of Clinical Oncology|2016Cited by 27